Publications

  • Search by Title

  • Search by Date

  • Select a Category

  • Reset
Eblasakimab, Translational work | May 21, 2024

Eblasakimab Significantly Alleviates IL-4 and IL-13-Induced Bronchial Airway Constriction in COPD-Derived Lung Slices

Ferda Cevikbas, Paul E Miller, Carl Firth
Eblasakimab Significantly Alleviates IL-4 and IL-13-Induced Bronchial Airway Constriction in COPD-Derived Lung Slices
Clinical publications, Eblasakimab | February 22, 2024

Safety and efficacy of eblasakimab, an interleukin 13 receptor α1 monoclonal antibody, in adults with moderate-to-severe atopic dermatitis: A phase 1b, multiple-ascending dose study

Karen A. Veverka, Steven T.G. Thng, Jonathan I. Silverberg, April W. Armstrong, Josemund Menezes, Alexandre Kaoukhov, Andrew Blauvelt
Veverka et al JAAD publication, October 2023
Eblasakimab, Translational work | November 6, 2023

Neuromodulation beyond itch is blocked by targeting IL-13Rα1 with eblasakimab

Yannick Miron, Paul Miller, Carl Firth, Ferda Cevikbas
Oral presentation at World Congress of Itch, 6 Nov 2023
Eblasakimab, Translational work | November 3, 2023

Combining Neuroscience And Immunology: Exploring The Neuro-immune Circuitry Behind Itch And Inflammation By Targeting IL-13Rα1With Eblasakimab

Ferda Cevikbas
7th Annual Dermatology Drug Development Summit (DDDS), November 2023
Eblasakimab, Translational work | October 27, 2023

Exploring the potential of farudodstat, a DHODH inhibitor, as an alopecia areata therapeutic in a novel ex vivo model of human hair follicle immune privilege collapse

Marta Bertolini
32nd European Academy of Dermatology and Venereology Congress (EADV), October 2023
Eblasakimab, Translational work | October 27, 2023

Downstream effects of IL-13Rα1 blockade on Th2-driven inflammation and Th1 immune axis activation in atopic dermatitis

Sriya V. Reddy, Zachary Bordeaux, Ahmad Rajeh, Darshan Sivaloganathan, Hannah Cornman, Anusha Kambala, Jackson Adams, Carl Firth, Ferda Cevikbas, Shawn G. Kwatra, Madan M. Kwatra
32nd European Academy of Dermatology and Venereology Congress (EADV), October 2023
Eblasakimab, Translational work | October 27, 2023

Neuromodulation beyond itch is blocked by targeting IL-13Rα1 with eblasakimab

Yannick Miron, Paul Miller, Carl Firth and Ferda Cevikbas
32nd European Academy of Dermatology and Venereology Congress (EADV), October 2023
Clinical publications, Eblasakimab | October 27, 2023

Eblasakimab Improves Multiple Disease Measures in Adult Patients with Moderate-to-severe Atopic Dermatitis in a Randomized, Double-blinded, Placebo-controlled, Phase 1 Study

Karen A. Veverka, Ferda Cevikbas, Steven Tien Guan Thng,Melinda Gooderham, Eric Simpson
25th World Congress of Dermatology, July 2023
Clinical publications, Eblasakimab | October 27, 2023

Topline results from TREK-AD: a randomized, double-blind, placebo-controlled, Phase 2b study of eblasakimab in adult patients with moderate-to-severe atopic dermatitis

Eric Simpson, Melinda Gooderham, Leon H Kircik, Todd Schlesinger, James Del Rosso, Dédée Murrell, Steven Thng, Jacek Szepietowski, Karen A Veverka, Alexandre Kaoukhov, April W. Armstrong
32nd European Academy of Dermatology and Venereology Congress (EADV), October 2023
Eblasakimab, Translational work | August 29, 2023

IL-13Rα1 Signaling in Atopic Dermatitis

Sriya V. Reddy, Zachary Bordeaux, Ahmed Rajeh, Jackson Adams, Ferda Cevikbas, Shawn G. Kwatra, Madan M. Kwatra
25th World Congress of Dermatology, July 2023
Eblasakimab, Translational work | August 29, 2023

Blocking multi-neuronal sensitization effects of IL-4 and IL-13 through Interleukin-13 receptor alpha 1 (IL-13Rα1) with eblasakimab

Yannick Miron, Paul Miller, Carl Firth and Ferda Cevikbas
25th World Congress of Dermatology, July 2023
Clinical publications, Eblasakimab | August 29, 2023

Eblasakimab Improves Itch and Sleep Loss in Adult Patients with Moderate-to-severe Atopic Dermatitis in a Randomized, Double-blinded, Placebo-controlled, Phase 1 Study

Karen A. Veverka, Steven Tien Guan Thng, Eric Simpson
25th World Congress of Dermatology, July 2023